Issue Date: April 23, 2012
GlaxoSmithKline Offers $2.6 Billion To Buy Human Genome Sciences
GlaxoSmithKline has made an unsolicited $2.6 billion bid for its long-standing partner Human Genome Sciences. The biotech firm has rejected the bid as too low and has hired Goldman Sachs and Credit Suisse to explore its options, including a sale to GSK or another firm.
GSK and HGS have been drug development and marketing partners since 1993, just two years after HGS was founded. To date, only one product . . .
You Do Not Have Access to C&EN Protected Content.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society